The Journal of allergy and clinical immunology
Cure8 research brief
Why This Matters
A tissue-based molecular panel that separates eosinophilic colitis from IBD could reduce diagnostic uncertainty when biopsies show high eosinophil counts and guide appropriate management, particularly in children and young adults.
Who Should Pay Attention
Clinicians (gastroenterologists, pathologists), researchers in IBD and eosinophilic gut disorders, pediatric patients and their caregivers facing diagnostic uncertainty
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
Researchers developed a 96-gene qPCR panel and derived two scores: an "EoC" score reflecting eosinophil-associated gene expression and an "IBD" score reflecting IBD-associated inflammatory pathways. In their multi-center cohort the EoC score correlated with peak eosinophil counts but could not by itself separate EoC from IBD.
Adding the IBD-specific score improved discrimination, allowing the combined approach to distinguish active IBD from EoC and from controls with high reported AUCs.
Keep In Mind
This summary is grounded in the article abstract. The study cohort was modest in size and enriched for pediatric/young-adult cases; full methods and broader validation are needed before clinical adoption.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationThe Journal of allergy and clinical immunology
AuthorsRichard J Taylor, Mari Yamaguchi, Lee A Denson +29 more
InstitutionDivision of Gastroenterology, Hepatology, and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedOct 28, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Serum leucine-rich α-2-glycoprotein and monocyte chemoattractant protein-1 as novel biomarkers for predicting vedolizumab response in patients with ulcerative colitis.
Blood biomarkers that predict vedolizumab response could help patients and clinicians choose the most effective therapy sooner and avoid ineffective treatments. The study suggests LRG and MCP‑1 may differentiate...
Risk Factors and Predictive Biomarkers for Postoperative Complications in Crohn's Disease Surgery: Systematic Review.
People with Crohn’s disease facing surgery may have varying risks of complications; better biomarkers and models could help tailor perioperative care and decision-making. The review signals active research toward more...
Crohn's Risk Stratification: Optimizing Patient Care - Medscape
Risk stratification helps identify people with Crohn's who are more likely to develop strictures, fistulas, or need surgery so clinicians can monitor and treat them more aggressively early on. Objective tests like fecal...